Evaluation of three herbal compounds used for the management of lower urinary tract disease in healthy cats: a pilot study

2017 ◽  
Vol 20 (12) ◽  
pp. 1094-1099 ◽  
Author(s):  
Melissa Daniels ◽  
Joseph W Bartges ◽  
Donna M Raditic ◽  
Steve Marsden ◽  
Sherry K Cox ◽  
...  

Objectives Lower urinary tract disease (LUTD) occurs commonly in cats, and idiopathic cystitis (FIC) and urolithiasis account for >80% of cases in cats <10 years of age. Although several strategies have been recommended, a common recommendation is to induce dilute urine resulting in more frequent urination and to dilute calculogenic constituents. In addition to conventional therapy using modified diets, traditional Chinese and Western herbs have been recommended, although only one – choreito – has published data available. We evaluated three commonly used herbal treatments recommended for use in cats with LUTD: San Ren Tang, Wei Ling Tang and Alisma. We hypothesized that these three Chinese herbal preparations would induce increased urine volume, decreased urine saturation for calcium oxalate and struvite, and differences in mineral and electrolyte excretions in healthy cats. Methods Six healthy spayed female adult cats were evaluated in a placebo-controlled, randomized, crossover design study. Cats were randomized to one of four treatments, including placebo, San Ren Tang, Wei Ling Tang or Alisma. Treatment was for 2 weeks each with a 1 week washout period between treatments. At the end of each treatment period, a 24 h urine sample was collected using modified litter boxes. Results Body weights were not different between treatments. No differences were found in 24 h urinary analyte excretions, urine volume, urine pH or urinary saturation for calcium oxalate or struvite between treatments. Conclusions and relevance The results of this study do not support the hypothesis; however, evaluation of longer-term and different dosage studies in cats with LUTD is warranted.

1999 ◽  
Vol 35 (4) ◽  
pp. 297-301 ◽  
Author(s):  
HM McClain ◽  
JA Barsanti ◽  
JW Bartges

Five cats that presented for signs of lower urinary tract disease (i.e., pollakiuria and hematuria) secondary to a calcium oxalate urolithiasis are presented. On evaluation, all five cats had elevations of both serum ionized as well as total serum calcium. The hypercalcemia resolved after discontinuation of urinary acidifying therapy or a dietary change, or both.


2020 ◽  
Vol 10 (4) ◽  
pp. 317-323
Author(s):  
Adel S. Al-Shukri ◽  
Stanislav V. Kostyukov

The results of the use of the phytopreparation Tadimax in the treatment of 60 men with mild and moderate lower urinary tract symptoms (LUTS) developed as a result of benign enlargement of the prostate gland are presented. The average age of the patients was 66.5 3.8 years. Tadimax was prescribed 2 tablets 3 times a day, in courses of 7 days with 7 day breaks for 3 months (a total of 6 courses). The data obtained indicate high efficacy and good tolerability of treatment. A decrease in the severity of LUTS was noted in 59 (96.6%) patients, which was accompanied by significant changes in objective clinical indicators: a decrease in residual urine volume and an increase in urine flow rate. Tadimax is a combined preparation, which includes extracts of several medicinal plants, and the main component is Crinum latifolium. The therapeutic effect of Tadimax is based on anti-inflammatory, antiproliferative and immunotropic action.


2014 ◽  
Vol 12 (4) ◽  
pp. 285-289 ◽  
Author(s):  
Hassan A. Abdelwahab ◽  
Housseini M. Abdalla ◽  
Mahmoud H. Sherief ◽  
Mohamed B. Ibrahim ◽  
Mostafa A. Shamaa

2018 ◽  
Author(s):  
Takumi Takeuchi ◽  
Satoshi Toyokawa ◽  
Yumiko Okuno ◽  
Noriko Ishida ◽  
Masanari Yamagoe ◽  
...  

AbstractLower urinary tract symptoms are widespread in elderly men and often suggestive of benign prostatic hyperplasia (LUTS/BPH). A randomized, prospective, and open-labeled trial directly comparing the effects of tadalafil (a phosphodiesterase 5 inhibitor) 5 mg once daily and tamsulosin (an α1-blocker) 0.2 mg once daily for 12 weeks in LUTS/BPH patients was conducted. Data were recorded before randomization as well as at 4, 8, and 12 weeks after medication. Fifteen patients allocated tadalafil and 20 allocated tamsulosin completed 12 weeks of medication. Total IPSS, IPSS voiding, and IPSS-QOL scores declined with medication, but there was no difference between drugs. IPSS storage scores reduced more in the tamsulosin group than tadalafil group. OABSS did not decline significantly with medication. IIEF5 was maintained in the tadalafil group, but declined in the tamsulosin group. The maximum flow rate and post-void residual urine volume did not significantly change with medication. Daytime, night-time, and 24-hour urinary frequencies as well as the mean and largest daytime, night-time, and 24-hour voiding volumes per void did not significantly change with medication. In conclusion, tamsulosin was more effective to reduce storage symptoms than tadalafil. Tadalafil had the advantage of maintaining the erectile function.


2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Claire S. Burton* ◽  
Gabriela Gonzalez ◽  
Yuliya Zektser ◽  
Corey Arnold ◽  
Christopher V. Almario ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document